Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Nov;34(6):e2579.
doi: 10.1002/rmv.2579.

The Assessment of Anti-SARS-CoV-2 Antibodies in Different Vaccine Platforms: A Systematic Review and Meta-Analysis of COVID-19 Vaccine Clinical Trial Studies

Mohammad Mirzakhani  1 , Maryam Bayat  2 , Mohammadreza Dashti  3   4 , Safa Tahmasebi  5 , Maryam Rostamtabar  6 , Hadi Esmaeili Gouvarchin Ghaleh  7 , Jafar Amani  1
Affiliations
Meta-Analysis

The Assessment of Anti-SARS-CoV-2 Antibodies in Different Vaccine Platforms: A Systematic Review and Meta-Analysis of COVID-19 Vaccine Clinical Trial Studies

Mohammad Mirzakhani et al. Rev Med Virol. 2024 Nov.

Abstract

Background and objective: The COVID-19 pandemic spread rapidly throughout the world and caused millions of deaths globally. Several vaccines have been developed to control the COVID-19 pandemic and reduce the burden it placed on public health. This study aimed to assess the efficacy of different vaccine platforms in inducing potent antibody responses. Moreover, the seroconversion rate and common side effects of vaccine platforms were evaluated.

Methods: This meta-analysis included clinical trials of COVID-19 vaccines that met the eligibility criteria. Electronic databases (including PubMed, Scopus, and Web of Science) and Google Scholar search engine were searched for eligible studies. Regarding the methodological heterogeneity between the included studies, we selected a random-effects model. The geometric mean ratio (GMR) was chosen as the effect size for this meta-analysis.

Results: Of the 1838 records identified through screening and after removing duplicate records, the full texts of 1076 records were assessed for eligibility. After the full-text assessment, 56 records were eligible and included in the study. Overall, vaccinated participants had a 150.8-fold increased rate of anti-spike IgG titres compared with the placebo group (GMR = 150.8; 95% CI, 95.9-237.1; I2 = 100%). Moreover, vaccinated participants had a 37.3-fold increased rate of neutralising antibody titres compared with the placebo group (GMR = 37.3; 95% CI, 28.5-48.7; I2 = 99%). The mRNA platform showed a higher rate of anti-spike IgG (GMR = 1263.5; 95% CI, 431.1-3702.8; I2 = 99%), while neutralising antibody titres were higher in the subunit platform (GMR = 53.4; 95% CI, 32.8-87.1; I2 = 99%) than in other platforms. Different vaccine platforms showed different rates of both anti-spike IgG and neutralising antibody titres with interesting results. The seroconversion rate of anti-spike IgG and neutralising antibody titres was more than 98% in the vaccinated participants.

Conclusion: Inactivated and subunit vaccines produced a high percentage of neutralising antibodies and had a low common adverse reaction rate compared to other platforms. In this regard, subunit and inactivated vaccines can still be used as the main vaccine platforms for effectively controlling infections with high transmission rates.

Keywords: COVID‐19; SARS‐CoV‐2; anti‐spike IgG; neutralising antibody; spike glycoprotein; trails; vaccine.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. S.‐M. Hsieh, M.‐C. Liu, Y.‐H. Chen, et al., “Safety and Immunogenicity of CpG 1018 and Aluminium Hydroxide‐Adjuvanted SARS‐CoV‐2 S‐2P Protein Vaccine MVC‐COV1901: Interim Results of a Large‐Scale, Double‐Blind, Randomised, Placebo‐Controlled Phase 2 Trial in Taiwan,” Lancet Respiratory Medicine 9, no. 12 (2021): 1396–1406, https://doi.org/10.1016/s2213‐2600(21)00402‐1.
    1. Web3, https://extranet.who.int/pqweb/vaccines/vaccinescovid‐19‐vaccine‐eul‐issued.
    1. M. D. Tanriover, H. L. Doğanay, M. Akova, et al., “Efficacy and Safety of an Inactivated Whole‐Virion SARS‐CoV‐2 Vaccine (CoronaVac): Interim Results of a Double‐Blind, Randomised, Placebo‐Controlled, Phase 3 Trial in Turkey,” Lancet 398, no. 10296 (2021): 213–222, https://doi.org/10.1016/s0140‐6736(21)01429‐x.
    1. K. J. Chappell, F. L. Mordant, Z. Li, et al., “Safety and Immunogenicity of an MF59‐Adjuvanted Spike Glycoprotein‐Clamp Vaccine for SARS‐CoV‐2: A Randomised, Double‐Blind, Placebo‐Controlled, Phase 1 Trial,” Lancet Infectious Diseases 21, no. 10 (2021): 1383–1394, https://doi.org/10.1016/s1473‐3099(21)00200‐0.
    1. G.‐L. Chen, X.‐F. Li, X.‐H. Dai, et al., “Safety and Immunogenicity of the SARS‐CoV‐2 ARCoV mRNA Vaccine in Chinese Adults: A Randomised, Double‐Blind, Placebo‐Controlled, Phase 1 Trial,” Lancet Microbe 3, no. 3 (2022): e193–e202, https://doi.org/10.1016/s2666‐5247(21)00280‐9.

MeSH terms